

March 25, 2013

Company name: KYORIN Holdings, Inc.

Representative: Masahiro Yamashita

Representative Director, President

(Securities Code: 4569, TSE 1st Sec.)

**Approval Received for PENTASA[®] Suppositories 1g,
a Drug for Ulcerative colitis.**

KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President: Mitsutomo Miyashita), a wholly owned subsidiary of KYORIN Holdings, Inc. announced today that PENTASA[®] Suppositories 1g, a new drug for the treatment of Ulcerative colitis was approved in Japan on March 25, 2013.

KYORIN Pharmaceutical Co., Ltd. has been marketing mesalazine drugs, PENTASA[®] Tablets 250mg, PENTASA[®] Tablets 500mg and PENTASA[®] Enema 1g in Japan while continuously engaging in the development for inflammatory bowel diseases (IBD), including Ulcerative colitis and Crohn's disease. The development of PENTASA[®] Suppositories 1g has just been successfully completed as a new formulation, which is convenient to patients, that meets therapeutic needs for Ulcerative colitis.

Ulcerative colitis is an intractable inflammatory bowel disease that frequently causes diarrhea and bloody bowel discharge, consequently hindering the daily lives of patients. There are no radical treatments since causes of the disease have yet to be identified. The current treatment goal is suppressing symptoms during the active phase as well as inducing and maintaining remission with the use of mesalazine drugs such as PENTASA[®] or steroids. Pathological lesions of the disease spread from the rectum in a continuous and ascending manner (toward the mouth). PENTASA[®] Suppositories 1g, which has just been approved for marketing, is expected to be highly effective for treating the pathological conditions in the rectum including blood feces as well as mucous and bloody stool.

Having been originally developed by Ferring (Switzerland), the drug has been approved for the treatments of IBD in 91 countries. It is widely used as a standard therapy.

With the addition of PENTASA[®] Suppositories 1g to other formulations in the product lineup, KYORIN Pharmaceutical Co., Ltd. will further contribute to treatment of patients with Ulcerative colitis by continuing to provide the latest medical information.